← Back to Calendar
Indication
PSMA PET imaging — new formulation for prostate cancer
Key Notes
New drug application for a new formulation of PYLARIFY PSMA PET imaging agent.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Advertisement